These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 15728824)

  • 1. Multiple myeloma.
    Altundag K; Altundag O; Gundeslioglu O
    N Engl J Med; 2005 Feb; 352(8):840-1; author reply 840-1. PubMed ID: 15728824
    [No Abstract]   [Full Text] [Related]  

  • 2. The incidence of jaw osteonecrosis in multiple myeloma patients treated with bisphosphonates.
    Kraj M; Pogłód R; Maj S; Owczarska K
    Acta Pol Pharm; 2006; 63(5):450-2. PubMed ID: 17357613
    [No Abstract]   [Full Text] [Related]  

  • 3. Osteonecrosis of the jaw and bisphosphonates.
    Durie BG; Katz M; Crowley J
    N Engl J Med; 2005 Jul; 353(1):99-102; discussion 99-102. PubMed ID: 16000365
    [No Abstract]   [Full Text] [Related]  

  • 4. [The complications during the therapy for multiple myeloma].
    Spicka I
    Vnitr Lek; 2006 Feb; 52(2):115. PubMed ID: 16623271
    [No Abstract]   [Full Text] [Related]  

  • 5. [Multiple myeloma].
    Abe M
    Nihon Rinsho; 2009 May; 67(5):991-5. PubMed ID: 19432122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced serum levels of Interleukin 17 in patients with osteonecrosis of the jaw and in multiple myeloma subjects after bisphosphonates administration.
    Oteri G; Allegra A; Bellomo G; Alonci A; Nastro E; Penna G; Catalfamo L; Cicciù D; De Ponte FS; Musolino C
    Cytokine; 2008 Aug; 43(2):103-4. PubMed ID: 18585926
    [No Abstract]   [Full Text] [Related]  

  • 7. Why osteonecrosis of the jaw after bisphosphonates treatment is more frequent in multiple myeloma than in solid tumors.
    Delibasi T; Altundag K; Kanlioglu Y
    J Oral Maxillofac Surg; 2006 Jun; 64(6):995-6. PubMed ID: 16713825
    [No Abstract]   [Full Text] [Related]  

  • 8. Bisphosphonates--role in cancer therapies.
    Mehrotra B
    J Oral Maxillofac Surg; 2009 May; 67(5 Suppl):19-26. PubMed ID: 19371811
    [No Abstract]   [Full Text] [Related]  

  • 9. Survey of members of myeloma UK on biphosphonates-associated jaw osteonecrosis.
    Barker K; Lowe D; Olujohungbe A; Low E; Rogers SN
    Br J Haematol; 2007 Nov; 139(4):626-8. PubMed ID: 17922879
    [No Abstract]   [Full Text] [Related]  

  • 10. [Osteonecrosis of the jaw in the course of multiple myeloma treatment and bisphosphonate administration].
    Adam Z; Kozumpliková M; Pour L; Machálka M
    Vnitr Lek; 2006 Feb; 52(2):176-80. PubMed ID: 16623282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The dilemma of jaw osteonecrosis in patients with multiple myeloma.
    Gertz MA; Koka S
    Leuk Lymphoma; 2008 Nov; 49(11):2037-9. PubMed ID: 19021045
    [No Abstract]   [Full Text] [Related]  

  • 12. Bisphosphonate-associated osteonecrosis of the jaw: conclusions based on an analysis of case series.
    Landesberg R; Wilson T; Grbic JT
    Dent Today; 2006 Aug; 25(8):52, 54-7. PubMed ID: 16925161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bisphosphonates, hypercalcemia of malignancy, and osteonecrosis of the jaw.
    Wynn RL
    Gen Dent; 2005; 53(6):392-5. PubMed ID: 16366043
    [No Abstract]   [Full Text] [Related]  

  • 14. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid.
    Dimopoulos MA; Kastritis E; Anagnostopoulos A; Melakopoulos I; Gika D; Moulopoulos LA; Bamia C; Terpos E; Tsionos K; Bamias A
    Haematologica; 2006 Jul; 91(7):968-71. PubMed ID: 16757414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Osteonecrosis of the jaw associated with the use of bisphosphonates in multiple myeloma: report of four cases and literature review].
    Li LH; Wu XB; Chen WM; Chen JX; Wu Y; Chen SL
    Zhonghua Yi Xue Za Zhi; 2008 Nov; 88(42):2986-7. PubMed ID: 19080077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bisphosphonate-induced osteonecrosis of the jaw: long-term outcomes.
    Katz J; George T; Sandow P; Machado M; Dickerson L; Moreb JS
    J Support Oncol; 2009; 7(1):9-10. PubMed ID: 19278171
    [No Abstract]   [Full Text] [Related]  

  • 17. Bisphosphonate-related osteonecrosis: genetic and acquired risk factors.
    Sarasquete ME; González M; San Miguel JF; García-Sanz R
    Oral Dis; 2009 Sep; 15(6):382-7. PubMed ID: 19413677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Avascular jaw osteonecrosis associated with bisphophonate therapy].
    Broglia C; Merlati G; Valentino F; Benatti C; Gobbi P; Ascari E
    Recenti Prog Med; 2006 Mar; 97(3):140-4. PubMed ID: 16700419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Jaw osteonecrosis related to bisphosphonate treatment of bone metastasis.
    Raffaelli L; Scaramuzzo L; Rossi Iommetti P; Graci C; Maccauro G; Manicone PF
    J Biol Regul Homeost Agents; 2010; 24(2):115-21. PubMed ID: 20487624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management.
    Ruggiero SL; Fantasia J; Carlson E
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2006 Oct; 102(4):433-41. PubMed ID: 16997108
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.